PMID- 9854580
OWN - NLM
STAT- MEDLINE
DCOM- 19990111
LR  - 20190915
IS  - 0039-6060 (Print)
IS  - 0039-6060 (Linking)
VI  - 124
IP  - 6
DP  - 1998 Dec
TI  - Prospective study of the utility of somatostatin-receptor scintigraphy in the 
      evaluation of patients with multiple endocrine neoplasia type 1.
PG  - 1037-42
AB  - BACKGROUND: Neuroendocrine tumors (NETs) are a potentially lethal component of 
      multiple endocrine neoplasia type 1 (MEN 1). Somatostatin receptor scintigraphy 
      (SRS) can be used to localize NETs and evaluate patients for 
      extraduodenopancreatic disease; its utility in managing MEN 1 is undefined. 
      METHODS: All patients with MEN 1 evaluated by SRS from April 1994 to November 
      1997 are reported. SRS findings were correlated with other imaging studies and 
      operative findings. RESULTS: Thirty-seven SRS studies were performed in 29 
      patients with MEN 1. SRS identified occult tumor in 36% (4/11) of patients with 
      only biochemical evidence of NET; 2 patients went on to resection. SRS showed 
      tumor in 79% (15/19) of patients with computed tomography (CT)-demonstrated 
      tumor; 30% (6/20) of the SRS lesions were occult on CT. Conversely, 55% (16/29) 
      of CT-identified lesions were occult on SRS. SRS found distant disease in 21% 
      (6/29) of patients. In patients who had previous operations, SRS found tumor in 
      40% (4/10) of patients, again with both new positive and false-negative results 
      compared with other imaging. SRS also had 3 important false-positive results, 
      including 1 patient who had laparotomy with no tumor identified. CONCLUSIONS: SRS 
      is useful in identifying otherwise occult NETs in patients with MEN 1 and can 
      substantially alter management. However, SRS also has significant false-positive 
      and false-negative results that demand correlation with other studies.
FAU - Yim, J H
AU  - Yim JH
AD  - Department of Surgery, Mallinckrodt Institute of Radiology, Washington University 
      School of Medicine, St Louis, Mo., USA.
FAU - Siegel, B A
AU  - Siegel BA
FAU - DeBenedetti, M K
AU  - DeBenedetti MK
FAU - Norton, J A
AU  - Norton JA
FAU - Lairmore, T C
AU  - Lairmore TC
FAU - Doherty, G M
AU  - Doherty GM
LA  - eng
GR  - 5P01-CA53524/CA/NCI NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Surgery
JT  - Surgery
JID - 0417347
RN  - 0 (Radiopharmaceuticals)
RN  - 0 (Receptors, Somatostatin)
RN  - 142694-57-3 (SDZ 215-811)
RN  - 7A314HQM0I (Pentetic Acid)
RN  - RWM8CCW8GP (Octreotide)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multiple Endocrine Neoplasia Type 1/*diagnostic imaging/*secondary
MH  - Octreotide/*analogs & derivatives
MH  - Pentetic Acid/*analogs & derivatives
MH  - Prospective Studies
MH  - Radionuclide Imaging
MH  - *Radiopharmaceuticals
MH  - Receptors, Somatostatin/*analysis
EDAT- 1998/12/17 00:00
MHDA- 1998/12/17 00:01
CRDT- 1998/12/17 00:00
PHST- 1998/12/17 00:00 [pubmed]
PHST- 1998/12/17 00:01 [medline]
PHST- 1998/12/17 00:00 [entrez]
AID - S0039-6060(98)70046-7 [pii]
AID - 10.1067/msy.1998.92553 [doi]
PST - ppublish
SO  - Surgery. 1998 Dec;124(6):1037-42. doi: 10.1067/msy.1998.92553.